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fd. Note - This overview was originally presented at the 
International Symposium on Clinical Disorders of Bone 
and Mineral Metabolism, May 9-13,1983. The following 
list indicates the presentations given in this session at the 
Symposium and the contents ofthe corresponding chap-
ter in the Proceedings of the Symposium published by 
Excerpta Medica. The numbers in parentheses refer to 
pages in this volume. Complete information about the 
contents of the Proceedings can be found at the back of 
this issue. 
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Use o f 1,25(Ohl)^D^ in the t r e a t m e n t o f r ena l os teodys-
t r o p h y in pa t ien ts w i t h m o d e r a t e rena l fa i lure. S.G. 
Massry, H. G r u b e r , A.S. R izv i , D. S h e r m a n , D.A. G o l d -
s te in , and J .M. Let ter i (260) 
Use o f ac t ive v i t am in D sterols in end-s tage rena l fa i lu re . 
J.W. C o b u r n , D.J. She r ra rd , S.A. O t t , N.C. D i D o m e n i c o , 
G.F. Bryce, A.S. B r i c k m a n , L.W. Bassett, E.G.C. W o n g , 
R.B. M i l l e r , C M . Bennet t , R.H. G o l d , O . N . M i l l e r , S.A. 
S h u p i e n , and P.C. Chang (263) 
S u p p r e s s i o n o f s e c o n d a r y h y p e r p a r a t h y r o i d i s m by 
1 , 2 5 ( O H ) P J . E. S la topo lsky, C. Wee r t s , B. Th ie l an , T. 
Ga lceran and K. M a r t i n (267) 
The m a n a g e m e n t o f a l u m i n i u m re la ted osteomalac ia in 
rena l fa i lure. P. A c k r i l l , J. Bal l , and J.P. Day (273) 
T h i s d iscuss ion of m i n e r a l m e t a b o l i s m and b o n e d is-
ease in rena l f a i l u r e f o c u s e d o n r ecen t d e v e l o p m e n t s ; 
m o r e c o m p l e t e d iscuss ion of these p r o b l e m s can be 
f o u n d in t h e l i t e r a t u r e (1,2). This r e v i e w summar i zes 
v iews o n t h e p a t h o g e n e s i s and m a n a g e m e n t o f t h e 
b o n e d iseases e n c o u n t e r e d in r e n a l f a i l u r e , w i t h 
emphas i s o n t h e c o n c e p t tha t m o r e t h a n o n e process 
acts t o d i s to r t m i n e r a l m e t a b o l i s m . 
Sher rard and co l leagues (pp . 254 ff.) s u m m a r i z e d a 15-
year eva lua t i on of pat ients w i t h end-s tage renal disease 
( E S R D ) , i n c l u d i n g c l in ica l f i nd ings , h i s t o m o r p h o m e t r i c 
s tudy o f b o n e , and results of s ta in ing b o n e sect ions fo r 
a l u m i n u m . A f t e r near ly t en years of expe r i ence admin i s -
t e r i n g act ive v i t a m i n D stero ls , t h e ind ica t ions fo r the i r 
use and the ef fects t o be expec ted rema in in d o u b t . 
Massry and co l leagues (pp . 260 ff.) p resen ted results o f a 
c o n t r o l l e d s tudy us ing ca lc i t r i o l (1 ,25(OH)2-v i tamin D3) 
in t r e a t m e n t of pat ients w i t h m o d e r a t e renal fa i lu re . M y 
r e v i e w (pp . 263 f f .) s u m m a r i z e d o u r data o n t h e use of 
ca lc i t r io l to treat or p reven t b o n e disease in dialysis 
pat ients . S la topolsky and co l leagues (pp . 267 ff.) p r e -
sented o the r new and s o m e w h a t d i f f e r e n t results w i t h 
paren tera l ca lc i t r io l . 
G r o w i n g ev idence indicates that t he a c c u m u l a t i o n of 
a l u m i n u m in b o n e can cause os teomalac ia in pat ients 
w i t h end-s tage u r e m i a . Ack r i l l and c o - w o r k e r s (pp . 273 
ff.) desc r ibed m e t h o d s fo r che la t i ng and r e m o v i n g a l u m -
i n u m f r o m the body . 
Pathogenesis of secondary h y p e r p a r a t h y r o i d i s m 
Secondary h y p e r p a r a t h y r o i d i s m , w h i c h is nearly un i ve r -
sal in pat ients w i t h renal i nsu f f i c i ency , o r ig ina tes ear ly in 
t h e course of progress ive k i dney disease, p resumab ly in 
response t o t rans ient h y p o c a l c e m i a . The most p r o b a b l e 
causes fo r hypoca lcemia are 1) phospha te r e ten t i on 
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secondary to a reduced renal capacity to excrete phos-
phate and 2) reduction in the renal generation of the 
hormone, 1,25(OH)2-vitamin D3. Skeletal responsiveness 
to the calcemic action of parathyroid hormone (PTH) is 
reduced, probably in consequence of the phosphate 
retention and reduced generation of calcitriol. 
The elegant studies of Slatopolsky, et a I (3,4) have shown 
that restricting dietary phosphate in proport ion to the 
magnitude of fall in the glomerular fi ltration rate (GFR) 
can largely prevent secondary hyperparathyroidism in 
dogs with experimental renal failure. These investigators 
postulated that serum phosphorus increases transiently 
as GFR falls early in the course of renal failure. The 
increments in serum phosphorus would lower blood 
calcium and thereby increase PTH secretion, which in 
turn would decrease tubular reabsorption of PO^ and 
cause phosphaturia. Serum phosphorus and calcium 
levels would return to normal, but only at the expense of 
a higher PTH level. This process would continue as renal 
failure progressed to the limit of inhibit ion of tubular 
PO4 reabsorption, i.e., GFR below 25-30 ml /m in . There-
after, persistent hyperphosphatemia would occur. The 
problem with this proposed theory is that serum phos-
phorus levels a re actually normal or even low in patients 
with modest renal insufficiency. However, in advanced 
renal failure, with marked hyperphosphatemia, there is 
no question that hypocalcemia and elevated serum 
immunoactive PTH (iPTH) levels are directly related to 
the serum phosphorus concentrations (5). 
Other data suggest that altered vitamin D metabolism 
contributes to the altered calcium and phosphorus 
homeostasis in uremia. Reduced generation of calcitriol 
with a consequent reduction in intestinal calcium absorp-
tion could contr ibute to developing secondary hyper-
parathyroidism, by causing hypocalcemia. Some studies 
(6) have shown that serum calcitriol levels are normal in 
patients with modest renal failure (GFR above 40 ml /min) ; 
however, children with moderate renal failure havesub-
normal serum 1,25(OH)2D concentrations (1). Through 
an effector mechanism not yet apparent, phosphate re-
tention in renal failure affects reduced calcitriol synthesis, 
increased PTH secretion, and secondary hyperparathy-
roidism. Thus, it is not possible to separate the effects of 
"PO4 retent ion" from alterations in "vitamin D metabo-
lism" (8) in the pathogenesis o f the secondary hyperpara-
thyroidism of renal failure because PO4 retention may 
inhibit the generation of 1,25(OH)2D (8); see Fig. 1. 
As reported by Brown (9), abnormalities of parathyroid 
cell function have been identif ied in uremic patients 
with secondary hyperparathyroidism. Both hyperplasia 
with increased cell number and alterations of cell func-
AI+++ OM 
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Fig.1 
Scheme showing the proposed pathogenesis of secondary hyperpara-
thyroidism and osteomalacia in renal failure. Abbreviations: GFR, 
glomerular filtration rate; OM, ostemalacia, OF, osteitis fibrosa; and 
SCa, serum calcium. 
t ion occur. The latter is identif ied by a rightward shift of 
the "set po in t " , defined as the ambient calcium level in 
the incubation media which affects half-maximal sup-
pression of PTH release by the isolated parathyroid cells. 
This abnormality has been found in cells from 70-80% of 
parathyroid glands taken from patients with secondary 
hyperparathyroidism due to ESRD (9), but factors respon-
sible for this shift in set point are unknown. In dialysis 
patients, the observation that elevated serum iPTH levels 
often are not reduced until the serum calcium exceeds 
normal concentrations is compatible with the concept of 
a rightward shift of the set point for PTH secretion (10). 
Because serum iPTH levels are often used in the evalua-
t ion of patients with ESRD, it is important to understand 
that renal failure exerts a major effect on the results of 
such assays which employ antisera that recognize the 
mid- or carboxyl-terminus o f the PTH molecule. Because 
glomerular f i l tration normally clears these PTH frag-
ments f rom plasma, they can accumulate in substantial 
amounts in the plasma of uremic patients (11). For most 
immunoassays, data are not available to indicate the 
" n o r m a l " level of iPTH in renal failure. Immunoassay 
laboratories often include results from all dialysis patients 
with secondary hyperparathyroidism in a nomogram 
displaying the relation between serum iPTH and serum 
calcium concentrations. In dialysis patients, such nomo-
grams have little value in detecting the presence of 
secondary hyperparathyroidism. Before serum iPTH assays 
can be used intelligently in formulat ing treatment for 
patients with renal failure, data must indicate the rela-
t ionship between serum iPTH levels and a target organ 
response such as histomorphometric changes in bone. 
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Pathogenesis of osteomalacia in end-stage renal failure 
Several factors can contr ibute to the development of 
osteomalacia in patients with renal failure. These include 
marked PO^ depletion and hypophosphatemia, coexist-
ent nutrit ional deficiency of vitamin D, and the use of 
anticonvulsant drugs. The calcitriol deficiency that is 
present in renal failure may also make uremic patients 
more prone to develop osteomalacia. However, the 
most common factor associated with vitamin D-refractory 
osteomalacia in renal patients is the accumulation of 
aluminum in bone. 
The data support ing aluminum as a pathogenetic factor 
are overwhelming: 
1) A luminum, whether f rom the dialysate or absorbed 
from the intestine, is retained in the absence of kidney 
function. 
2) A strong association exists between the aluminum 
content of water used to prepare dialysate and the inci-
dence of osteomalacia in dialysis patients. 
3) A luminum accumulates along the calcification f ronto f 
bone, and little or no tetracycline uptake occurs at sites 
where there is aluminum accumulation. 
4) Aluminum injections can cause osteomalacia in animals. 
5) Inadvertent infusions of a luminum, as has occurred in 
certain parenteral nutr i t ion solutions, can cause osteo-
malacia in humans. 
6) Treatment with the chelating agent, desferrioxamine, 
which can remove aluminum, has been reported anec-
dotally to produce improvement in dialysis osteomalacia. 
The magnitude of the problem of bone disease asso-
ciated with aluminum accumulation is unknown. It is 
possible that some other retained substance could also 
cause low-turnover osteomalacia in patients who have 
lost renal excretory capacity. If so, renal patients who do 
not have aluminum accumulation may be found to have 
refractory osteomalacia. 
Management of calcium metabolism in renal failure 
In secondary hyperparathyroidism, it is important to pre-
vent hyperphosphatemia and maintain serum calcium 
levels within an acceptable range. The goals of clinical 
practice are listed in Table I. The first is to prevent hyper-
phosphatemia both by reducing dietary PO^ and by 
using PO^-binding antacids. Contro l of hyperphos-
phatemia can prevent or reverse the extraskeletal calcifi-
cations that were common during the early period after 
dialysis was first introduced. Phosphate restriction can 
aid also in control l ing secondary hyperparathyroidism. 
TABLE I 
Principles of Management of Minera l Metabol ism in ESRD 
Control Serum P 
(4.0-5.5 mg/dl) 
Restrict diet PO^ (<1 g/d) 
PO^-binding gels 
Adequate Ca Intake (#1 1st) 
Dialysate Calcium 
(3.0-3.5 mEq/L) 
Vitamin D Sterols (#1 1st) 
Rx of secondary 
hyperparathyroidism 
FHypocalcemia 
Prevent bone disease* 
Chi ldren with ESRD 
Forms: Sterol wi th 1a-OH 
group is preferred 
4. Miscellaneous 
Water purif ication to remove 
aluminum, f lourine: control 
magnesium, calcium 
Normalize b lood phi 
Normalize serum magnesium 
Avoid unneeded 
anticonvulsants 
Chelate a luminum* 
5. Parathyroidectomy indicated 
for: 
Overt secondary 
hyperparathyroidism 
Failure of 1, 2, and 3 
Calciphylaxis 
*Place in management is not established. 
Once serum phosphorus is control led, methods should 
be used to raise the serum calcium to normal. These 
include adjusting dialysate calcium levels to 3.3-3.7 
mEq/L to prevent calcium loss, as well as adding calcium 
supplements to the diet. The active vitamin D sterols 
[calcitriol, dihydrotachysterol,1-alpha-(OH)-vitamin D3, 
and calcifediol (25-OH-D3)] may also be used to maintain 
the serum calcium concentration. Other papers in this 
Symposium dealt more fully with the clinical effects of 
the active vitamin D sterols. Finally, parathyroidectomy is 
the treatment of choice for certain patients with overt 
secondary hyperparathyroidism. However, the presence 
of vitamin D-refractory osteomalacia, which is often 
accompanied by hypercalcemia (12), must be excluded, 
for this syndrome either fails to improve or may worsen 
after parathyroidectomy (12,13). 
Prevention and treatment of osteomalacia 
Ackril l and associates (pp. 270 ff.) emphasized that 
patients undergoing hemodialysis must receive appro-
priate water treatment. The occasional development of 
vitamin D refractory osteomalacia in uremic patients 
who have never undergone dialysis indicates that ingested 
aluminum-containing compounds may be the source of 
a luminum. When aluminum-associated osteomalacia 
develops, rigid dietary phosphate restriction and reduc-
t ion in the dose of PO.,-binders is indicated. The use of 
calcium-carbonate to reduce PO^ absorption has been 
employed by Mor in iere, et al (14), and the use of desfer-
rioxamine was discussed by Ackri l l . 
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Other procedures which are employed wi thout critical 
proof of efficacy in the treatment of secondary hyper-
parathyroidism include correction of acidosis, preven-
tion of hypermagnesemia, and avoidance of f luoride in 
the dialysate. The loss of vitamin D sterols either into the 
urine of patients with the nephrotic syndrome or into 
peritoneal dialysate during treatment with continuous 
ambulatory peritoneal dialysis may increase the vitamin 
D requirements. We lack valid data on the efficacy of 
replacement treatment under these conditions. 
Table II lists some unanswered questions and problems 
related to bone and mineral metabolism in patients with 
renal failure. Some of these questions were answered in 
this Symposium; others are awaiting further study. 
TABLE II 
Some Unanswered Questions About Renal Osteodystrophy 
Pathogenesis 4 
• Flow does PO .-retention 
act? 
• wha t is mechanism for the 
"set po in t " shift? 
• How important is PTFH as a 
"uremic toxin?" 
• wha t is role of acidosis? 
Types of bone diseases 
• w h a t is s ign i f i cance of 
these? 
Prevention 
• When to restrict diet PO, 
• When to add calcitriol? 
In managing established ESRD, 
Use of D sterols: 
• When to use? 
• Which to use? 
• Do their effects differ? 
• Flow do they act? 
• When to add calcium 
supplements? 
• When to do parathyroid-
ectomy? 
Wi th "DialysisOsteomalacia," 
• Are there causes other than 
aluminum? 
• Flow can a luminum be 
removed? 
• Flow is a luminum 
absorbed? 
• Does a luminum removal 
help? 
• Do high PTH levels help? 
• What are safe and effective 
PO^-binders lacking 
aluminum? 
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